Business News • PR NewsWire • Additional Analyses From Phase 3 study With Doptelet ® (avatrombopag) for the treatment of Chronic Immune Thrombocytopenia Provides Evidence of Long-term Response Rates

Additional Analyses From Phase 3 study With Doptelet ® (avatrombopag) for the treatment of Chronic Immune Thrombocytopenia Provides Evidence of Long-term Response Rates

Additional Analyses From Phase 3 study With Doptelet ® (avatrombopag) for the treatment of Chronic Immune Thrombocytopenia Provides Evidence of Long-term Response Rates

STOCKHOLM, Dec. 9, 2019 /PRNewswire/ -- Dova Pharmaceuticals, a wholly owned subsidiary of Swedish Orphan Biovitrum AB (publ) (Sobi™), presented additional analyses from the phase 3 study - core and extension phase - with avatrombopag (AVA) for the treatment of immune thrombocytopenia...

View More : https://www.prnewswire.com:443/news-releases/additional-analyses-from-phase-3-study-with-doptelet--avatrombopag-for-the-...

Releted News by prnewswire

Nurish.Me Inc. Releases Audited Financial Statements for 2017 and 2018

Celadon Group, Inc. and Affiliates Commence Voluntary Chapter 11 Cases

New XPG CPU Cooler Incorporates Asetek Liquid Cooling Technology for Advanced Overclocking Capability

Additional Analyses From Phase 3 study With Doptelet ® (avatrombopag) for the treatment of Chronic Immune Thrombocytopenia Provides Evidence of Long-term Response Rates

Life Time Launches Three Exclusive New Classes Expanding High-Powered Programming into 2020

The Geneva Association Launches New Women in Insurance Award